Pulmonary hypertension (PH) has a profound impact on the identity and sexuality of the women who live with the…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Hospital-based administrative data can be used to identify patients with pulmonary hypertension (PH) in medical records, according to a…
Among people who have had a heart attack, those with pulmonary hypertension (PH) are at high risk of heart…
Measuring levels of protein sLR11 in the blood could be useful in testing for pulmonary hypertension (PH) in people…
The use of imaging to evaluate the right side of the heart could be useful for non-invasively diagnosing and monitoring…
In addition to lowering blood pressure, treatments for pulmonary arterial hypertension (PAH) probably work at least in part by…
People with pulmonary hypertension are at increased risk of developing cancer, especially lung and skin cancers, a new study…
Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial…
Pulmonary Hypertension News brought you the latest coverage of advances in treatment, clinical trials, and scientific research related to…
Care at a specialty center is tied to a lower risk of hospitalization for people with heart failure with preserved ejection fraction…
Children with pulmonary arterial hypertension (PAH) report poorer health-related quality of life (HRQoL) than their peers, a study shows.
Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib,…